Previous 10 | Next 10 |
home / stock / cdmop / cdmop news
TUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical com...
TUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotec...
TUSTIN, Calif. and MORGAN HILL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufactu...
TUSTIN, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biote...
Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry Named 2020 CMO Leadership Award Champion in Categories of Expertise and Service TUSTIN, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioser...
Avid Bioservices, Inc. (CDMO) Q3 2020 Earnings Conference Call March 10, 2020, 16:30 ET Company Participants Tim Brons - Vida Strategic Partners Richard Hancock - Interim President, CEO & Director Daniel Hart - CFO Timothy Compton - Chief Commercial Officer Conference Ca...
-- Recorded Third Quarter Revenue of $13.6 Million -- -- Signed New Customer and Project Expansion Orders with Current Customers for $20 Million -- -- Adjusting Fiscal 2020 Projected Revenue to $55 to $59 Million -- TUSTIN, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- A...
TUSTIN, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotec...
-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed -- -- Launched Expanded Process Development Facility and Services -- TUSTIN, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE)...
TUSTIN, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical com...
News, Short Squeeze, Breakout and More Instantly...
Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock Company Name:
CDMOP Stock Symbol:
NASDAQ Market:
Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock Website:
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditur...
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announc...
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and phar...